Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer

ABSTRACT: BACKGROUND: Triple-negative breast cancer (TNBC) is a uniquely aggressive cancer with high rates of relapse due to resistance to chemotherapy. TNBC expresses higher levels of programmed cell death-ligand 1 (PD-L1) compared to other breast cancers, providing the rationale for the recently a...

Descripción completa

Detalles Bibliográficos
Autores principales: Camorani, Simona, Passariello, Margherita, Agnello, Lisa, Esposito, Silvia, Collina, Francesca, Cantile, Monica, Di Bonito, Maurizio, Ulasov, Ilya V., Fedele, Monica, Zannetti, Antonella, De Lorenzo, Claudia, Cerchia, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487859/
https://www.ncbi.nlm.nih.gov/pubmed/32892748
http://dx.doi.org/10.1186/s13046-020-01694-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487859/
https://www.ncbi.nlm.nih.gov/pubmed/32892748
http://dx.doi.org/10.1186/s13046-020-01694-9

Ejemplares similares